# 2026-16438: NIH Licenses Drug-Switchable Cancer-Killing T-Cells Invention Now

2026-16438, NIH Owned Invention Available for License: Drug-Regulatable, Inducible Expression of Membrane-Bound Interleukin 12 (DRIM-IL-12) for Use in Adoptive Cell Therapy, is a Federal Register notice from Health and Human Services Department, National Institutes of Health published 2026-08-12 (as of 2026-08-19).

- Canonical: https://policyrisk.com/federal-register/2026-16438
- As of: 2026-08-19
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-16438
- Title: NIH Owned Invention Available for License: Drug-Regulatable, Inducible Expression of Membrane-Bound Interleukin 12 (DRIM-IL-12) for Use in Adoptive Cell Therapy
- Type: Notice
- Agencies: Health and Human Services Department; National Institutes of Health
- Citation: 91 FR 52063
- Published: 2026-08-12
- Effective: unknown
- Comments close: not stated
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-08-19

## In one line

NIH Licenses Drug-Switchable Cancer-Killing T-Cells Invention Now

## Summary

The NIH has created a smart new way to boost cancer-fighting T-cells using a drug-controlled system called DRIM-IL-12. This tech helps T-cells attack tumors better and safer by turning on only when needed and can be dialed down with a drug to avoid side effects. Researchers and companies can now license this invention to help bring better cancer treatments to patients faster.

## Abstract

Scientists at the National Cancer Institute (NCI) have developed a novel tightly regulated drug-responsive, membrane-bound IL- 12 cytokine platform, that enhances anti-tumor efficacy in adoptive cell therapy (ACT) with engineered T-cells (CAR, TCR, TILs) while improving safety. The NCI seeks research co-development partners and/or licensees to advance this technology toward clinical translation.

## Effects PRIA read

No economic effects identified for this document.

## Related documents

- [2026-22871](https://policyrisk.com/federal-register/2026-22871): Center for Scientific Review; Notice of Closed Meetings, 2026-11-10
- [2026-22550](https://policyrisk.com/federal-register/2026-22550): Center for Scientific Review; Notice of Closed Meetings, 2026-11-05
- [2026-22558](https://policyrisk.com/federal-register/2026-22558): Center for Scientific Review; Notice of Closed Meetings, 2026-11-05
- [2026-22339](https://policyrisk.com/federal-register/2026-22339): Prospective Grant of Exclusive Patent License: Catheter-Based Intramyocardial Ablation for Treating Ventricular Arrhythmia in a Human, 2026-11-02
- [2026-22196](https://policyrisk.com/federal-register/2026-22196): National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Meeting, 2026-10-30
- [2026-22111](https://policyrisk.com/federal-register/2026-22111): Eunice Kennedy Shriver National Institute of Child Health & Human Development; Notice of Meeting, 2026-10-29

## Sources
- [2026-16438 on federalregister.gov](https://www.federalregister.gov/documents/2026/08/12/2026-16438/nih-owned-invention-available-for-license-drug-regulatable-inducible-expression-of-membrane-bound)
- [2026-16438 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-08-12/pdf/2026-16438.pdf)

## Related
- [Previous: 2026-16437, Agency Information Collection Activities; Proposed eCollection eComments Reques…](https://policyrisk.com/federal-register/2026-16437)
- [Next: 2026-16439, Government Owned Invention Available for License: Quantitative Particle Identif…](https://policyrisk.com/federal-register/2026-16439)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-16438 (as of 2026-08-19).